Product information
From Health Canada
The product monograph is developed by a drug sponsor according to guidelines published by Health Canada that provide direction on the content and format. The veterinary labelling is developed by the drug sponsor according to the Food and Drug Regulations. While Health Canada reviews the product monograph or the veterinary labelling as part of the drug review process, it remains the responsibility of the drug sponsor to ensure that the product monograph or the veterinary labelling is complete and accurate.
Current status:
Marketed
Current status date:
2017-03-27
Original market date: See footnote 1
2010-07-29
Product name:
MENVEO
Description:
1 VIAL LYOPH. MEN. A CONJUGATE & 1 VIAL SOL. MEN. CWY CONJUGATE
DIN:
02347393
Product Monograph/Veterinary Labelling:
Date:
2020-06-03
Product monograph/Veterinary Labelling (PDF version ~ 175K)
Company:
GLAXOSMITHKLINE INC
800
100 Milverton Drive
Mississauga
Ontario
Canada
L5R 4H1
Class:
Human
Dosage form(s):
Solution , Powder For Solution
Route(s) of administration:
Intramuscular
Number of active ingredient(s):
5
Schedule(s):
Schedule D
American Hospital Formulary Service (AHFS): See footnote 3
80:12.00
Anatomical Therapeutic Chemical (ATC): See footnote 4
J07AH08 MENINGOCOCCUS, A, C, Y, W-135, TETRAVAL. PURIFIED POLYSACC. ANTIGEN CONJUGATED
Active ingredient group (AIG) number:See footnote5
0552705002
| Active ingredient(s) | Strength |
|---|---|
| CORYNEBACTERIUM DIPHTHERIAE CRM-197 PROTEIN | 47 MCG / 0.5 ML |
| MENINGOCOCCAL GROUP A OLIGOSACCHARIDE | 10 MCG / 0.5 ML |
| MENINGOCOCCAL GROUP C OLIGOSACCHARIDE | 5 MCG / 0.5 ML |
| MENINGOCOCCAL GROUP W-135 OLIGOSACCHARIDE | 5 MCG / 0.5 ML |
| MENINGOCOCCAL GROUP Y OLIGOSACCHARIDE | 5 MCG / 0.5 ML |
Risk Management Plans See footnote 7
A Risk Management Plan (RMP) for this product was submitted.